Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo ...

Axsome Therapeutics’ AXSM shares have rallied ... s portfolio of pipeline candidates includes AXS-07, AXS-12 and AXS-14, all of which are being developed for various CNS indications.

Axsome Therapeutics (AXSM – Research Report ... The potential regulatory approvals for AXS-07, AXS-14, and AXS-12 in the near to medium term, along with the expected submission of AXS-05 ...

Ratings for Axsome Therapeutics AXSM were provided ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit ...

17 analysts have expressed a variety of opinions on Axsome Therapeutics AXSM ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment ...

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Axsome's lead candidate ... Some analysts project that AXS-05 could generate over $500 million in AD agitation revenue five years post-launch, with a 14% peak penetration rate.

Axsome Therapeutics’ AXSM shares have rallied ... Axsome’s commercial portfolio includes Auvelity (AXS-05) which was launched in the United States in 2022 to treat major depressive disorder.